Daniel spent 12 years at Novartis in three Divisions including Pharma in Basel, Switzerland, Vaccines & Diagnostics in Emeryville, CA, USA and Sandoz (Generics / Biopharmaceuticals) in Holzkirchen / Munich, Germany. He held various line function roles spanning from Research to Sales across the three businesses including Global Franchise Head Strategic Marketing for Immunology & Infectious Diseases and Global Head Marketing Transplantation in Pharma, Global Head of Development, Diagnostics and Global Head New Product & Portfolio Strategy Biopharmaceuticals at Sandoz.
He currently serves as a member of the Board of Directors at MicrobeDx, Inc. Los Angeles, CA.
He oversaw and was a team member for multiple collaborations, licensing deals and acquisitions from academic to multi-billion dollar transactions, world-wide commercial launches and FDA / EMA / CFDA / ANVISA registrations with respective clinical trials. His therapeutic disease area expertise includes Oncology/Hematology, Immunology (including Rheumatology, Dermatology, Gastroenterology), Infectious Diseases (Virology and Bacteriology), Solid Organ Transplantation and Nephrology. Prior to Novartis he was at McKinsey & Company, Inc. e.g., implementing DRGs and disease management programs for statutory and private health insurance companies, leading a turnaround case for an acute specialty hospital. He was also a juror and coach at the German Science 4 Life Venture Cup for 7 years from inception.
He is an MD from Johannes-Gutenberg-University Mainz, Germany with clinical training in Germany, Switzerland and the USA (UC Davis Medical Center, Sacramento, CA) and was a scientific co-worker at the Institute for Occupational, Social and Environmental Medicine in Mainz for several years. German-Indonesian, with wife and two daughters, he is a retired tennis and soccer league player. Now an active sailor he is also the Chairman of the Board for a growing Waldorf School south of Munich.